NASDAQ:GANX Gain Therapeutics (GANX) Stock Price, News & Analysis → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free GANX Stock Alerts $2.55 +0.04 (+1.59%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$2.48▼$2.6750-Day Range$2.34▼$3.9952-Week Range$2.00▼$5.33Volume192,223 shsAverage Volume123,573 shsMarket Capitalization$46.03 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Gain Therapeutics alerts: Email Address Gain Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside233.3% Upside$8.50 Price TargetShort InterestHealthy0.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.34Based on 9 Articles This WeekInsider TradingAcquiring Shares$115,800 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.11) to ($1.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.93 out of 5 starsMedical Sector406th out of 924 stocksPharmaceutical Preparations Industry187th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingGain Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGain Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Gain Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.60% of the float of Gain Therapeutics has been sold short.Short Interest Ratio / Days to CoverGain Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gain Therapeutics has recently decreased by 34.70%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGain Therapeutics does not currently pay a dividend.Dividend GrowthGain Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GANX. Previous Next 3.0 News and Social Media Coverage News SentimentGain Therapeutics has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Gain Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Gain Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gain Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $115,800.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders11.70% of the stock of Gain Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.97% of the stock of Gain Therapeutics is held by institutions.Read more about Gain Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Gain Therapeutics are expected to decrease in the coming year, from ($1.11) to ($1.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gain Therapeutics is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gain Therapeutics is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGain Therapeutics has a P/B Ratio of 5.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Gain Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyBill Clinton Backing Biden Replacement???Bill Clinton is back. And he just met in Mexico with the one person I believe could REPLACE Joe Biden by August…Click here now for my urgent election forecast. About Gain Therapeutics Stock (NASDAQ:GANX)Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Read More GANX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GANX Stock News HeadlinesMay 30 at 7:00 AM | globenewswire.comGain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024May 30 at 1:30 AM | americanbankingnews.comEquities Analysts Set Expectations for Gain Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:GANX)May 28, 2024 | americanbankingnews.comGain Therapeutics (NASDAQ:GANX) Stock Rating Reaffirmed by HC WainwrightMay 15, 2024 | finanznachrichten.deGain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate UpdateMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Gain Therapeutics Amid Positive Clinical and Financial PerformanceMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Gain Therapeutics Amidst Promising Clinical Trials and Strong Financial HealthMay 14, 2024 | globenewswire.comGain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate UpdateApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Gain Therapeutics on Promising GT-02287 Clinical ProgressApril 24, 2024 | markets.businessinsider.comGain Therapeutics Announces Positive Phase 1 Results For GT-02287 In GBA1 Parkinson's Disease TrialApril 24, 2024 | finance.yahoo.comGain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseApril 24, 2024 | globenewswire.comGain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's DiseaseApril 20, 2024 | investing.comGain Therapeutics Inc (GANX)April 17, 2024 | finance.yahoo.comHere's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom FisherApril 8, 2024 | finanznachrichten.deGain Therapeutics, Inc.: Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial OfficerApril 8, 2024 | markets.businessinsider.comGain Therapeutics Appoints Gene Mack As CFO; Stock FallsApril 8, 2024 | globenewswire.comGain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial OfficerApril 4, 2024 | msn.comFormer Gildan CEO considered acquisition of Hanesbrands - BloombergApril 1, 2024 | finance.yahoo.comDirector Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)April 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Gain Therapeutics on Promising Parkinson’s Treatment and Solid Financial OutlookApril 1, 2024 | finance.yahoo.comGain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical OfficerMarch 28, 2024 | markets.businessinsider.comOptimistic Buy Rating for Gain Therapeutics Backed by Strong Financials and Promising Parkinson’s Drug Candidate GT-02287March 27, 2024 | finanznachrichten.deGain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate UpdateMarch 26, 2024 | globenewswire.comGain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate UpdateMarch 15, 2024 | globenewswire.comGain Therapeutics to Present at Public Ventures Discovery DayMarch 5, 2024 | msn.comEXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's DiseaseSee More Headlines Receive GANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today6/02/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GANX CUSIPN/A CIK1819411 Webwww.gaintherapeutics.com Phone301-500-1556FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+233.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,270,000.00 Net MarginsN/A Pretax Margin-40,210.22% Return on Equity-213.34% Return on Assets-129.04% Debt Debt-to-Equity Ratio0.05 Current Ratio2.77 Quick Ratio2.77 Sales & Book Value Annual Sales$50,000.00 Price / Sales920.55 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book5.31Miscellaneous Outstanding Shares18,050,000Free Float15,940,000Market Cap$46.03 million OptionableOptionable Beta0.52 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Khalid Islam Ph.D. (Age 69)Founder & Chairman Comp: $75kMr. Matthias Alder LIC. IUR. (Age 59)LL.M., President, CEO & Director Comp: $593kMr. Gene Mack M.B.A.Chief Financial OfficerDr. Manolo Bellotto Ph.D. (Age 53)GM & Chief Strategy Officer Comp: $251.99kDr. Joanne Taylor Ph.D.Senior Vice President of ResearchDr. Terenzio Ignoni Pharm.D.Senior Vice President of Technical OperationsDr. Jonas Hannestad M.D.Ph.D., Chief Medical OfficerMore ExecutivesKey CompetitorsEvogeneNASDAQ:EVGNPassage BioNASDAQ:PASGHookipa PharmaNASDAQ:HOOKX4 PharmaceuticalsNASDAQ:XFORTrevi TherapeuticsNASDAQ:TRVIView All CompetitorsInsidersJeffrey Scott RileyBought 30,000 shares on 3/28/2024Total: $115,800.00 ($3.86/share)Matthias AlderSold 206 sharesTotal: $506.76 ($2.46/share)View All Insider Transactions GANX Stock Analysis - Frequently Asked Questions Should I buy or sell Gain Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gain Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GANX shares. View GANX analyst ratings or view top-rated stocks. What is Gain Therapeutics' stock price target for 2024? 4 brokers have issued 1 year price objectives for Gain Therapeutics' shares. Their GANX share price targets range from $6.00 to $10.00. On average, they expect the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 233.3% from the stock's current price. View analysts price targets for GANX or view top-rated stocks among Wall Street analysts. How have GANX shares performed in 2024? Gain Therapeutics' stock was trading at $3.27 on January 1st, 2024. Since then, GANX stock has decreased by 22.0% and is now trading at $2.55. View the best growth stocks for 2024 here. Are investors shorting Gain Therapeutics? Gain Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 100,700 shares, a decrease of 34.7% from the April 30th total of 154,200 shares. Based on an average daily volume of 116,600 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.6% of the company's stock are sold short. View Gain Therapeutics' Short Interest. When is Gain Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our GANX earnings forecast. How were Gain Therapeutics' earnings last quarter? Gain Therapeutics, Inc. (NASDAQ:GANX) posted its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.03. When did Gain Therapeutics IPO? Gain Therapeutics (GANX) raised $40 million in an IPO on Thursday, March 18th 2021. The company issued 3,600,000 shares at $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager. How do I buy shares of Gain Therapeutics? Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GANX) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsWrite this ticker symbol down…StocksToTradeTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBill Clinton Backing Biden Replacement???The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
